Daniel J. Becker - Net Worth and Insider Trading

Daniel J. Becker Net Worth

The estimated net worth of Daniel J. Becker is at least $237 Million dollars as of 2024-06-05. Daniel J. Becker is the Director of Pandion Therapeutics Inc and owns about 2,827,883 shares of Pandion Therapeutics Inc (PAND) stock worth over $170 Million. Daniel J. Becker is the Director of Principia Biopharma Inc and owns about 667,600 shares of Principia Biopharma Inc (PRNB) stock worth over $67 Million. Daniel J. Becker is also the Director of Day One Biopharmaceuticals Inc and owns about 5,000 shares of Day One Biopharmaceuticals Inc (DAWN) stock worth over $63,850. Besides these, Daniel J. Becker also holds Acelyrin Inc (SLRN) . Details can be seen in Daniel J. Becker's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Daniel J. Becker has not made any transactions after 2023-05-09 and currently still holds the listed stock(s).

Transaction Summary of Daniel J. Becker

To

Daniel J. Becker Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Daniel J. Becker owns 4 companies in total, including Principia Biopharma Inc (PRNB) , Pandion Therapeutics Inc (PAND) , and Day One Biopharmaceuticals Inc (DAWN) among others .

Click here to see the complete history of Daniel J. Becker’s form 4 insider trades.

Insider Ownership Summary of Daniel J. Becker

Ticker Comapny Transaction Date Type of Owner
PRNB Principia Biopharma Inc 2020-09-28 director
PAND Pandion Therapeutics Inc 2020-11-19 director & 10 percent owner
DAWN Day One Biopharmaceuticals Inc 2021-06-01 director
LIMIT LIMIT 2023-05-09 director

Daniel J. Becker Latest Holdings Summary

Daniel J. Becker currently owns a total of 4 stocks. Among these stocks, Daniel J. Becker owns 2,827,883 shares of Pandion Therapeutics Inc (PAND) as of November 19, 2020, with a value of $170 Million and a weighting of 71.75%. Daniel J. Becker owns 667,600 shares of Principia Biopharma Inc (PRNB) as of November 20, 2019, with a value of $67 Million and a weighting of 28.22%. Daniel J. Becker also owns 5,000 shares of Day One Biopharmaceuticals Inc (DAWN) as of June 1, 2021, with a value of $63,850 and a weighting of 0.03%. The other 1 stocks Acelyrin Inc (SLRN) have a combined weighting of 0.01% among all his current holdings.

Latest Holdings of Daniel J. Becker

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
PAND Pandion Therapeutics Inc 2020-11-19 2,827,883 60.05 169,814,374
PRNB Principia Biopharma Inc 2019-11-20 667,600 100.05 66,793,380
DAWN Day One Biopharmaceuticals Inc 2021-06-01 5,000 12.77 63,850
SLRN Acelyrin Inc 2023-05-09 3,000 4.26 12,780

Holding Weightings of Daniel J. Becker


Daniel J. Becker Form 4 Trading Tracker

According to the SEC Form 4 filings, Daniel J. Becker has made a total of 3 transactions in Pandion Therapeutics Inc (PAND) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in Pandion Therapeutics Inc is the acquisition of 197,716 shares on November 19, 2020, which cost Daniel J. Becker around $3 Million.

According to the SEC Form 4 filings, Daniel J. Becker has made a total of 3 transactions in Principia Biopharma Inc (PRNB) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in Principia Biopharma Inc is the acquisition of 55,000 shares on November 20, 2019, which cost Daniel J. Becker around $2 Million.

According to the SEC Form 4 filings, Daniel J. Becker has made a total of 1 transactions in Day One Biopharmaceuticals Inc (DAWN) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Day One Biopharmaceuticals Inc is the acquisition of 5,000 shares on June 1, 2021, which cost Daniel J. Becker around $80,000.

More details on Daniel J. Becker's insider transactions can be found in the Insider Trading History of Daniel J. Becker table.

Insider Trading History of Daniel J. Becker

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Daniel J. Becker Trading Performance

GuruFocus tracks the stock performance after each of Daniel J. Becker's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Daniel J. Becker is 41.19%. GuruFocus also compares Daniel J. Becker's trading performance to market benchmark return within the same time period. The performance of stocks bought by Daniel J. Becker within 3 months outperforms 7 times out of 9 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Daniel J. Becker's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Daniel J. Becker

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
1 out of 3 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 6.71 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 3.83 LIMIT LIMIT LIMIT LIMIT LIMIT

Daniel J. Becker Ownership Network

Ownership Network List of Daniel J. Becker

No Data

Ownership Network Relation of Daniel J. Becker

Insider Network Chart

Daniel J. Becker Owned Company Details

What does Principia Biopharma Inc do?

Who are the key executives at Principia Biopharma Inc?

Daniel J. Becker is the director of Principia Biopharma Inc. Other key executives at Principia Biopharma Inc include Chief Medical Officer Dolca Thomas , Chief Development Officer Stefani Wolff , and Chief Scientific Officer David M Goldstein .

Principia Biopharma Inc (PRNB) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Principia Biopharma Inc (PRNB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Principia Biopharma Inc (PRNB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Principia Biopharma Inc (PRNB)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Principia Biopharma Inc Insider Transactions

No Available Data

Daniel J. Becker Mailing Address

Above is the net worth, insider trading, and ownership report for Daniel J. Becker. You might contact Daniel J. Becker via mailing address: C/o New Leaf Venture Partners, Times Sq Tower, 7 Times Sq, Ste 3502, New York Ny 10036.

Discussions on Daniel J. Becker

No discussions yet.